HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Professor Christoph Zielinski

Professor Zielinski is director of the Clinical Division of Oncology and Chairman of the Department of Medicine at Medical University of Vienna, Austria. He serves as coordinator of the Comprehensive Cancer Centre at Medical University of Vienna (www.ccc.ac.at) and the General Hospital in Vienna, Austria and is President of the Central European Cooperative Oncology Group (CECOG, www.cecog.org). Professor Zielinski completed his medical training at the University Hospital Vienna and began his career with a position as a research fellow at the Cancer Research Center at Tufts University, Boston. His recent clinical research activities cover a wide range of cancer therapies, with particular focus on clinical trials, breast cancer research and treatment and development of targeted drugs.

Professor Zielinski is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO).

Professor Zielinski serves on a series of committees of the European Society of Medical Oncology (ESMO) and is the current President nominee of ESMO.

He has published more than 420 original research papers and reviews in peer‐reviewed journals.

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551